{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin&page=10", "query": { "intervention": "Rosuvastatin", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 222, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T13:29:34.267Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07820891", "title": "A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Participants" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Dabigatran etexilate", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2026-09-25", "completion_date": "2026-11-22", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07820891" }, { "nct_id": "NCT04833764", "title": "Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Post-thrombotic Syndrome", "Deep Vein Thrombosis Leg" ], "interventions": [ { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Khanh Nguyen", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2021-06-01", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04833764" }, { "nct_id": "NCT05906836", "title": "A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 28, "start_date": "2023-07-27", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05906836" }, { "nct_id": "NCT01702987", "title": "Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myopathy", "HMG COA Reductase Inhibitor Adverse Reaction", "Hypercholesterolemia" ], "interventions": [ { "name": "ubiquinol", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "statin", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2012-10", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01702987" }, { "nct_id": "NCT00767130", "title": "DNA Diagnostic System for Statin Safety and Efficacy", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hypercholesterolemia", "Myopathy" ], "interventions": [], "intervention_types": [], "sponsor": "Genomas, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2007-01", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2008-10-06", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 3, "location_summary": "San Francisco, California • Hartford, Connecticut • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767130" }, { "nct_id": "NCT03532139", "title": "Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Enoxaparin + Rosuvastatin", "type": "DRUG" }, { "name": "Thromboprophylaxis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2018-07-25", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532139" }, { "nct_id": "NCT01730053", "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2012-11-30", "completion_date": "2014-05-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 54, "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730053" }, { "nct_id": "NCT07372625", "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "TP53 Y220C Mutation", "Advanced Solid Tumors" ], "interventions": [ { "name": "metformin hydrochloride 500 mg tablet", "type": "DRUG" }, { "name": "rosuvastatin 10 mg tablet", "type": "DRUG" }, { "name": "repaglinide 0.5 mg tablet", "type": "DRUG" }, { "name": "midazolam hydrochloride syrup", "type": "DRUG" }, { "name": "rezatapopt", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-02-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07372625" }, { "nct_id": "NCT03511118", "title": "Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lactating Women on Select DOI", "Breastfed Infants of Mothers on Select DOI" ], "interventions": [ { "name": "Tranexamic acid (TXA)", "type": "DRUG" }, { "name": "labetalol", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "nifedipine", "type": "DRUG" }, { "name": "clindamycin", "type": "DRUG" }, { "name": "oxycodone", "type": "DRUG" }, { "name": "azithromycin", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "sertraline", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Levofloxacin", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Cyclobenzaprine", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" }, { "name": "Trazodone", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Amoxicillin", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1600, "start_date": "2018-10-04", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 20, "location_summary": "La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511118" }, { "nct_id": "NCT01623115", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 486, "start_date": "2012-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-17T13:29:34.267Z", "location_count": 26, "location_summary": "Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01623115" } ] }